Qualitative analysis of major constituents from Xue Fu Zhu Yu Decoction using ultra high performance liquid chromatography with hybrid ion trap time‐of‐flight mass spectrometry

Fu, Chunyan; Xia, Zian; Liu, Yonghui; Lü, Hongmei; Zhang, Zhimin; Wang, Yang; Fan, Xiaqiong

doi:10.1002/jssc.201600083

Cited by 22 publications

(15 citation statements)

References 26 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xue-Fu-Zhu-Yu decoction (XFZYD) is a famous traditional Chinese medicine formula that has been used to manage with cardiovascular disorders for several centuries [10]. The study of Lee et al [11] suggested that XFZYD increased the potential of recombinant tissue plasminogen activator (tPA) as a neuroprotection agent against rat brain ischemia.…”

Section: Introductionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundRetinal ischemia-related eye diseases result in visual dysfunction. This study investigates the protective effects and mechanisms of Xue-Fu-Zhu-Yu decoction (XFZYD) with respect to retinal ischemia.MethodsRetinal ischemia (I) was induced in Wistar rats by a high intraocular pressure (HIOP) of 120 mmHg for 1 h, which was followed by reperfusion of the ischemic eye; the fellow untreated eye acted as a control. Electroretinogram (ERG), biochemistry and histopathology investigations were performed.ResultsSignificant ischemic changes occurred after ischemia including decreased ERG b-wave ratios, less numerous retinal ganglion cells (RGCs), reduced inner retinal thickness, fewer choline acetyltransferase (ChAT) labeled amacrine cell bodies, increased glial fibrillary acidic protein (GFAP) immunoreactivity and increased vimentin Müller immunolabeling. These were accompanied by significant increases in the mRNA/protein concentrations of vascular endothelium growth factor, hypoxia-inducible factor-1α, pyruvate kinase M2 and retinoblastoma-binding protein 2. The ischemic changes were concentration-dependently and significantly altered when XFZYD was given for seven consecutive days before or after retina ischemia, compared to vehicle. These alterations included enhanced ERG b-wave amplitudes, more numerous RGCs, enhanced inner retinal thickness, a greater number of ChAT immunolabeled amacrine cell bodies and decreased GFAP/vimentin immunoreactivity. Furthermore, decreased mRNA levels of VEGF, HIF-1α, PKM2, and RBP2 were also found. Reduced protein concentrations of VEGF, HIF-1α, PKM2, and RBP2 were also demonstrated. Furthermore, there was an inhibition of the ischemia-associated increased ratios (target protein/β-actin) in the protein levels of VEGF, HIF-1α, PKM2, and RBP2, which were induced by Shikonin, JIB-04 or Avastin.ConclusionXFZYD would seem to protect against well-known retinal ischemic changes via a synergistic inhibition of RBP2 and PKM2, as well as down-regulation of HIF-1α and a reduction in VEGF secretion.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-017-1857-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…M17 showed a [M + H] + ion at m/z 255.0557 and a [M−H] − ion at m/z 253.0498, and the formula was calculated as C 15 H 10 O 4 , which was 2 Da (2H) less than the protonated ion of liquiritigenin. The produced major fragment ions at m/z 209.1142 [M–H–CO 2 ] − , 135.0315 [M–H–C 8 H 6 O] – , and 117.1369 [M–H–C 7 H 4 O 3 ] – were found in negative mode . M17 was tentatively identified as the dehydrogenation version of liquiritigenin.…”

Section: Resultsmentioning

confidence: 99%

Identification of metabolites in human and rat urine after oral administration of Xiao‐Qing‐Long‐Tang granule using ultra high performance liquid chromatography combined with quadrupole time‐of‐flight mass spectrometry

Zhou

Zhang

et al. 2017

J of Separation Science

View full text Add to dashboard Cite

Xiao-Qing-Long-Tang is a traditional Chinese formula used for the treatment of cold syndrome, bronchitis, and nasal allergies for thousands of years. However, the in vivo integrated metabolism of its multiple components and the active chemical constituents of Xiao-Qing-Long-Tang remain unknown. In this study, a method using ultra high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry was established for the detection and identification of the metabolites in human and rat urine after oral administration of Xiao-Qing-Long-Tang. A total of 19 compounds were detected or tentatively identified in human urine samples, including eight prototypes and 11 metabolites. Also, a total of 50 compounds were detected or tentatively identified in rat urine samples, including 15 prototypes and 35 metabolites detected with either a highly sensitive extracted ion chromatogram method or the MS determination using Mass Fragment software. Our results indicated that phase Ⅱ reactions (e.g. glucuronidation and sulfation) were the main metabolic pathways of flavones, while phase I reactions (e.g. demethylation and hydroxylation) were the major metabolic reaction for alkaloids, lignans, and ginger essential oil. This investigation provided important structural information on the metabolism of Xiao-Qing-Long-Tang and provided evidence to obtain a more comprehensive metabolic profile.

show abstract

“…This regulation contains several proteins which consist of certain pathways (Figure 2A ). The CIDs of the 34 identified compounds of XFZYD were submitted into BATMAN-TCM [ 37 , 41 ]. Interestingly, the results showed that the main druggable target-LTP pathway was anchored by KEGG enrichment analysis.…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, we aimed to investigate whether XFZYD provided a synaptic regulation to improve cognitive function after TBI. The PubChem Compound IDs (CIDs) of the key compounds of XFZYD were submitted into BATMAN-TCM to predict the druggable targets related to synaptic function [ 37 , 41 ]. We further verified this prediction by molecular biological methods (Immunohistochemical, RT-PCR and western blot analyses).…”

Section: Introductionmentioning

confidence: 99%

Xuefu zhuyu decoction improves cognitive impairment in experimental traumatic brain injury via synaptic regulation

et al. 2017

Self Cite

View full text Add to dashboard Cite

An overarching consequence of traumatic brain injury (TBI) is the cognitive impairment. It may hinder individual performance of daily tasks and determine people's subjective well-being. The damage to synaptic plasticity, one of the key mechanisms of cognitive dysfunction, becomes the potential therapeutic strategy of TBI. In this study, we aimed to investigate whether Xuefu Zhuyu Decoction (XFZYD), a traditional Chinese medicine, provided a synaptic regulation to improve cognitive disorder following TBI. Morris water maze and modified neurological severity scores were performed to assess the neurological and cognitive abilities. The PubChem Compound IDs of the major compounds of XFZYD were submitted into BATMAN-TCM, an online bioinformatics analysis tool, to predict the druggable targets related to synaptic function. Furthermore, we validated the prediction through immunohistochemical, RT-PCR and western blot analyses. We found that XFZYD enhanced neuroprotection, simultaneously improved learning and memory performances in controlled cortical impact rats. Bioinformatics analysis revealed that the improvements of XFZYD implied the Long-term potentiation relative proteins including NMDAR1, CaMKII and GAP-43. The further confirmation of molecular biological studies confirmed that XFZYD upregulated the mRNA and protein levels of NMDAR1, CaMKII and GAP-43. Pharmacological synaptic regulation of XFZYD could provide a novel therapeutic strategy for cognitive impairment following TBI.

show abstract

Qualitative analysis of major constituents from Xue Fu Zhu Yu Decoction using ultra high performance liquid chromatography with hybrid ion trap time‐of‐flight mass spectrometry

Cited by 22 publications

References 26 publications

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Identification of metabolites in human and rat urine after oral administration of Xiao‐Qing‐Long‐Tang granule using ultra high performance liquid chromatography combined with quadrupole time‐of‐flight mass spectrometry

Xuefu zhuyu decoction improves cognitive impairment in experimental traumatic brain injury via synaptic regulation

Contact Info

Product

Resources

About